Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29634495 | 0.91 | KMT2A (0.76) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL1116738 | 0.91 | KMT2A (0.76) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL9809561 | 0.88 | RAB9A (0.76) | KMT2AMEN1CYP1A2CYP3A4TDP1 | |
| SCHEMBL17822214 | 0.88 | EPHX2 (0.75) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL4189041 | 0.87 | KMT2A (0.64) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL5553203 | 0.86 | KMT2A (0.72) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL4189064 | 0.86 | KMT2A (0.64) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL5483064 | 0.86 | EPHX2 (0.73) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL9763664 | 0.86 | EPHX2 (0.73) | GAAKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL2227019 | 0.86 | KMT2A (0.65) | GAAKMT2AMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763350-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-03-21 | — | — | EP | claimed |
| WO-2006014168-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-02-09 | — | — | WO | claimed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | GAA 2671/4885KMT2A 661/4885MEN1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.